Richard Daniell's most recent trade in Teva- Pharmaceutical Industries Ltd. - ADR was a trade of 69,182 Restricted Share Units done . Disclosure was reported to the exchange on March 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 69,182 | 69,182 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Sale of securities on an exchange or to another person at price $ 15.90 per share. | 05 Mar 2025 | 48,385 | 48,384 (0%) | 0% | 15.9 | 769,370 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 22,576 | 119,345 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 22,576 | 0 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Sale of securities on an exchange or to another person at price $ 15.91 per share. | 05 Mar 2025 | 22,576 | 96,769 (0%) | 0% | 15.9 | 359,272 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 183,169 | 0 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 183,169 | 183,169 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Sale of securities on an exchange or to another person at price $ 15.73 per share. | 04 Mar 2025 | 56,385 | 126,784 (0%) | 0% | 15.7 | 887,195 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 33,512 | 33,512 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 33,512 | 33,512 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Sale of securities on an exchange or to another person at price $ 15.91 per share. | 04 Mar 2025 | 30,015 | 96,769 (0%) | 0% | 15.9 | 477,635 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Sale of securities on an exchange or to another person at price $ 15.73 per share. | 04 Mar 2025 | 21,870 | 11,641 (0%) | 0% | 15.7 | 344,116 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 20,461 | 20,461 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 20,461 | 61,384 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Sale of securities on an exchange or to another person at price $ 15.73 per share. | 04 Mar 2025 | 13,353 | 7,108 (0%) | 0% | 15.7 | 210,104 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Sale of securities on an exchange or to another person at price $ 15.91 per share. | 04 Mar 2025 | 11,641 | 0 (0%) | 0% | 15.9 | 185,246 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Sale of securities on an exchange or to another person at price $ 15.91 per share. | 04 Mar 2025 | 7,108 | 0 (0%) | 0% | 15.9 | 113,111 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 62,250 | 62,250 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 62,250 | 124,503 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Sale of securities on an exchange or to another person at price $ 16.19 per share. | 03 Mar 2025 | 49,314 | 12,936 (0%) | 0% | 16.2 | 798,172 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Sale of securities on an exchange or to another person at price $ 15.56 per share. | 03 Mar 2025 | 12,936 | 0 (0%) | 0% | 15.6 | 201,253 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 183,169 | 183,169 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Sale of securities on an exchange or to another person at price $ 17.30 per share. | 12 Aug 2024 | 98,943 | 0 (0%) | 0% | 17.3 | 1,711,447 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 55,226 | 124,996 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 55,226 | 0 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Sale of securities on an exchange or to another person at price $ 13.52 per share. | 05 Mar 2024 | 26,053 | 98,943 (0%) | 0% | 13.5 | 352,117 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 22,576 | 22,576 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 22,576 | 92,346 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Sale of securities on an exchange or to another person at price $ 13.52 per share. | 05 Mar 2024 | 22,576 | 69,770 (0%) | 0% | 13.5 | 305,124 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2024 | 81,845 | 81,845 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 62,250 | 186,753 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Sale of securities on an exchange or to another person at price $ 13.34 per share. | 03 Mar 2024 | 62,250 | 69,770 (0%) | 0% | 13.3 | 830,247 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 62,250 | 132,020 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 33,512 | 103,282 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2024 | 33,512 | 67,024 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Sale of securities on an exchange or to another person at price $ 13.34 per share. | 03 Mar 2024 | 33,512 | 69,770 (0%) | 0% | 13.3 | 446,960 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Sale of securities on an exchange or to another person at price $ 13.12 per share. | 28 Feb 2024 | 20,599 | 69,770 (0%) | 0% | 13.1 | 270,176 | Ordinary Shares |
| Teva- Pharmaceutical Indus... | Daniell Richard | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 20,599 | 90,369 (0%) | 0% | - | Ordinary Shares | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 20,599 | 0 | - | - | Restricted Share Units | |
| Teva- Pharmaceutical Indus... | Richard Daniell | Exec. VP, European Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2024 | 55,226 | 55,226 | - | - | Restricted Share Units |